Chemomab Therapeutics (CMMB) Net Cash Flow (2017 - 2023)
Chemomab Therapeutics' (CMMB) quarterly Net Cash Flow came in at $140000.0 in Q4 2023, down 94.96% YoY from $2.8 million in Q4 2022, and up 111.4% on a QoQ basis from -$1.2 million in Q3 2023.
Chemomab Therapeutics (CMMB) Net Cash Flow (2017 - 2023) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Net Cash Flow data on file, last reported at $140000.0 in Q4 2023.
- Quarterly Net Cash Flow fell 94.96% year-over-year to $140000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $140000.0 (up 108.81% YoY) and the FY2025 annual result came in at $1.4 million, up 143.99% from the prior year.
- Net Cash Flow rose to $140000.0 in Q4 2023, from -$1.2 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $46.5 million in Q1 2021 to a low of -$22.6 million in Q4 2021.
- A 5-year average of $357750.0 and a median of -$1.3 million in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 3368.03% in 2021, down 2166.93% in 2021.
- Tracing CMMB's Net Cash Flow over 5 years: stood at -$5.7 million in 2019, then jumped by 82.43% to -$995000.0 in 2020, then plunged by 2166.93% to -$22.6 million in 2021, then jumped by 112.32% to $2.8 million in 2022, then slumped by 94.96% to $140000.0 in 2023.
- The last three Net Cash Flow figures came in at $140000.0 (Q4 2023), -$1.2 million (Q3 2023), and -$10.4 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 140,000.00 |
| Dec 31, 2023 | 140,000.00 |
| Sep 30, 2023 | -1.23 Mn |
| Sep 30, 2023 | -1.23 Mn |
| Jun 30, 2023 | -10.39 Mn |
| Jun 30, 2023 | -10.39 Mn |
| Mar 31, 2023 | 7.25 Mn |
| Mar 31, 2023 | 7.25 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Sep 30, 2022 | 858,000.00 |
| Sep 30, 2022 | 858,000.00 |
| Jun 30, 2022 | -3.95 Mn |
| Jun 30, 2022 | -3.95 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -22.56 Mn |
| Dec 31, 2021 | -22.56 Mn |
| Sep 30, 2021 | -7.65 Mn |
| Sep 30, 2021 | -7.65 Mn |